Analyst Coverage Change
On Tuesday January 24th, Telsey Advisory Group(Rank#75) issued a research report on Amazon, maintaining the Outperform rating on the stock, and lowering the target to $125 from $140.
Last weeks Ratings:
- STA Research maintains a “Buy” rating and has a target price of USD 125 on January 19, 2023.
- MKM Partners lowered their target price from USD 145 to USD 125 on January 18, 2023 and still maintains a “Buy” rating.
- Goldman Sachs maintains a “Buy” rating and lowered their target price from USD 165 to USD 145 on January 13, 2023.
- Cowen maintains an “Outperform” rating and lowered their target price from USD 160 to USD 140 on January 11, 2023.
- Jefferies Financial LLC lowered their target price to USD 125 on January 10, 2023.
Amazon Stock Forecast & Analysis
Amazon.com Inc’s stock forecasts from 41 analysts have an average target price of USD 149.11 over the next 12 months. The average analyst rating for Amazon.com Inc is Strong Buy, indicating a positive outlook for the company’s stock. Stock Target Advisor’s own analysis of Amazon.com Inc is Slightly Bullish, which is based on 6 positive signals and 4 negative signals. This analysis suggests that there are some positive indicators for the company’s stock, but also some negative factors to consider.
At the last closing, Amazon.com Inc’s stock price was USD 97.52. The stock price has changed by -0.61% over the past week, indicating a small decrease in value. However, over the past month, the stock price has risen by 14.39%, indicating a significant increase in value. In contrast, over the last year, the stock price has decreased by 31.63%. This suggests that the stock’s value has been quite volatile, but has generally trended downwards over the past year.
Prime Drug Prescription
Amazon has launched a subscription service called RxPass, which allows Prime members to purchase multiple drugs for a flat fee of $5 a month. The service allows patients to order generic medications that treat over 80 common health conditions, with free delivery included. The subscription service is available in most US states, but currently excludes some heavily populated ones such as California, Pennsylvania, and Texas. The program’s includes 53 available medications that are supported by the service. This move is Amazon’s push into healthcare, in a means to expand the comapny’s existing user base.
STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.
